Evgeniya V. Kazantseva

Evgeniya V. Kazantseva

Auto-generated profile, based on publicly available information

Evgeniya V. Kazantseva

Sechenov First Moscow State Medical University; Sklifosovsky Research Institute of Emergency Medicine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
ATAida I. Tarzimanova
Aida I. Tarzimanova
ABAnna E. Bragina
Anna E. Bragina
EKEvgeniya V. Kazantseva
Evgeniya V. Kazantseva
APAnna E. Pokrovskaya
Anna E. Pokrovskaya
NDNatalia A. Dragomiretskaya
Natalia A. Dragomiretskaya
VPValery I. Podzolkov
Valery I. Podzolkov
Background: Chronic obstructive pulmonary disease (COPD) is a frequent cause of atrial fibrillation (A-fib). A paroxysm of A-fib will protract the patients’ stay at hospital and increase their lethality risk considerably. Despite extensive research done in this field, the predictors of A-fib recurrence in COPD patients have not been definitively studied. Methods: Our single-institution prospective study involved 569 patients hospitalized for COPD exacerbation. Depending on whether they developed an A-fib paroxysm while in hospital, we divided the patients into two groups: group I (the main one) was composed of 111 COPD patients whose electrocardiogram (ECG) showed an A-fib paroxysm during hospitalization, and group II (the comparison group) comprised 458 COPD patients who had no A-fib paroxysm in their entire hospitalization period. All the patients were given a comprehensive clinical, laboratory, and instrumental examination that included a complete blood count and blood chemistry test, coagulogram, room air oxygen saturation test, external respiration test, standard ECG, echocardiogram, Holter daily ECG monitoring, and a chest computed tomography (CT) scan. Results: In exacerbated COPD patients, arterial hypertension (AH) would increase their risk of developing an A-fib paroxysm by a factor of 3.74 (confidence interval (CI) 2.78 - 4.19). Arrhythmic patients’ Charlson Comorbidity Index was veritably higher (5 (3 - 6) points) than in the comparison group (3 (2 - 5) points) (P = 0.004). A-fib patients had considerably lower oxygen saturation on room air (SpO2) (91.8% (89-95%)) than non-arrhythmic patients (95.2% (91-97%)). Right atrial area enlargement would increase exacerbated COPD patients’ risk of developing an A-fib paroxysm by a factor of 1.34 (1.16 - 1.56). A-fib patients were found to have a veritably raised level of C-reactive protein to 21.0 mg/L (5.65 - 35.2 mg/L), compared to non-arrhythmic patients with 8.3 mg/L (1.31 - 16.4 mg/L). Conclusion: The development of an A-fib paroxysm in patients hospitalized for exacerbated COPD is predicted by Charlson Comorbidity Index above 4, right atrial area enlargement, and heightened C-reactive protein.

21 January 2025 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ATA. I. Tarzimanova
A. I. Tarzimanova
EKE. V. Kazantseva
E. V. Kazantseva
AIAlexander Ivannikov
Alexander Ivannikov
NZN. K. Ziskina
N. K. Ziskina
VPV. I. Podzolkov
V. I. Podzolkov
Aim.  To assess the relationship between right atrial (RA) dilation and paroxysmal atrial fibrillation (AF) in patients with hypertension (HTN) and chronic obstructive pulmonary disease (COPD). Material and methods.  This retrospective cross-sectional study included 369 patients with HTN and COPD, who were divided into 2 following groups: group I — 68 (18,42%) hypertensive patients with COPD and paroxysmal AF; group II (comparison group) — 301 (81,57%) patients with HTN and COPD without arrhythmia. Results.  Patients in group I had significantly higher RA area and left atrial (LA) volume index (LAVI) than patients in group II. Multivariate regression analysis revealed that the RA area and LAVI were associated with paroxysmal AF in comorbid patients with HTN and COPD. To assess the relationship between atrial size and paroxysmal AF in patients with HTN and COPD, we developed a mathematical model with the following equation: р=1/(1+e -z )*100%, z=-12,51+0,130*LAVI+0,408*RAA, where p is the probability of having paroxysmal AF (%), RAA — RA area (cm 2 ); LAVI — left atrial volume index (ml/m 2 ). The p-value ≥24% indicates a high probability of paroxysmal AF (area under the ROC curve (AUC) =0,89, sensitivity — 80%, specificity — 77%). Conclusion.  RA dilation is associated with paroxysmal AF in patients with HTN and COPD — odds ratio (OR) 1,50; 95% confidence interval: 1,27-1,79.

2 July 2024 in Digital Diagnostics
Verified
Journal Article
Open access
PDF file
EKEvgeniya V. Kazantseva
Evgeniya V. Kazantseva
AIAlexander Ivannikov
Alexander Ivannikov
ATAida I. Tarzimanova
Aida I. Tarzimanova
VPValery I. Podzolkov
Valery I. Podzolkov
BACKGROUND: Arterial hypertension and chronic obstructive pulmonary disease have a deleterious effect on the structure of the heart, leading to the development of atrial fibrillation, which remains the leading cause of cerebral stroke and premature death [1]. Consequently, the early identification of atrial fibrillation risk factors in patients with arterial hypertension and chronic obstructive pulmonary disease is of paramount importance for the prevention of such conditions. This is why predictive cardiology employs machine learning methods, which are demonstrably superior to classical statistical methods of prediction [2–4]. AIM: The study aimed to develop a prognostic model of atrial fibrillation in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease based on multilayer perceptron. MATERIALS AND METHODS: The study included 419 patients treated at the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University. Group 1 consisted of 91 (21.7%) patients with a verified diagnosis of atrial fibrillation, while Group 2 comprised 328 (78.3%) patients without atrial fibrillation. The random forest machine learning algorithm was used to identify predictors, which were then utilized to develop a neural network of the multilayer perceptron type. This consisted of two layers: an input layer of 12 neurons with the ReLU activation function and an output layer that receives input data from the previous layer and transmits them to one output with the sigmoid activation function. The threshold value, sensitivity, specificity, and diagnostic efficiency of the obtained model were determined using receiver operating characteristic analysis with the calculation of the area under the curve (AUC). RESULTS: By the first stage of prognostic model development, the most significant predictors of atrial fibrillation development were selected by the random forest machine learning algorithm. The model was developed using three variables: C-reactive protein concentration (odds ratio, OR 1.04; 95% confidence interval, CI 1.015–1.067; p=0.002), erythrocyte sedimentation rate (OR 1.04; 95% CI 1.019–1.069; p=0.002), and creatinine concentration (OR 1.03; 95% CI 1.011–1.042; p 0.001). These variables were used to train a multilayer perceptron model on a test sample for 500 epochs. Following training, the developed model exhibited a sensitivity of 85%, a specificity of 80%, and a diagnostic efficiency of 79.6%. AUC amounted to 0.900. CONCLUSIONS: The study resulted in the development of a prognostic model based on the application of machine learning methods, which exhibited favorable metrics. This model may be considered a valuable tool for clinical practice.

21 January 2024 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
AIAlexander Ivannikov
Alexander Ivannikov
EKE. V. Kazantseva
E. V. Kazantseva
ADA. M. Demianov
A. M. Demianov
AKA. A. Kanibolotskiy
A. A. Kanibolotskiy
KAKh. G. Alidzhanova
Kh. G. Alidzhanova
SPS. S. Petrikov
S. S. Petrikov
   INTRODUCTION. Despite the improvements and success in the management of thrombosis, the prognosis of thrombotic complications in comorbid patients remains extremely unfavorable. Understanding this problem suggests that it is rational to pay more attention to the prevention of thrombosis in order to avoid thrombotic complications in the first place, and there is an urgent need to improve the ability to predict the development of complications and, most importantly, death. Therefore, some inexpensive, but effective methods of risk assessment need to be developed and integrated in clinical practice.   AIM OF STUDY. To assess which laboratory markers can be associated with higher probability of fatal outcome in patients with thrombotic complications.   MATERIAL AND METHODS. The retrospective cross-sectional study included 283 patients who were admitted to the N.V. Sklifosovsky Research Institute for Emergency Medicine in 2021. Minimum age was 21 years, maximum age was 96 years, median age – 68 (59,0; 76,5) years. 161 (56,9 %) patients were males, 122 (43,1 %) – females. Group I included 226 patients with thrombotic complications; Group II included 57 (20,1 %) patients who died during hospitalization. The patients were diagnosed with the following thrombotic complications: pulmonary embolism (PE) was diagnosed in 28 (9.9 %), acute coronary syndrome with ST segment elevation in 38 (13.4 %), arterial thrombosis in 84 (29.7 %), venous thrombosis in 54 (19.1 %), thrombophlebitis in 22 (7.8 %), and systemic thromboembolism in 7 (2.5 %) patients.   RESULTS. It was established that the decrease in the estimated glomerular filtration to the levels of stage 3 (and lower) chronic kidney disease (AUC — 0,881, sensitivity — 86.92 %, specificity — 85.71 %), hemoglobin level — to less than 120 g/L (AUC — 0,690, sensitivity — 77,21 %, specificity — 55,1 %), as well as hypoalbuminemia (AUC — 0,905, sensitivity — 78,89 %, specificity — 91,18 %) statistically significantly increased the likelihood of death by 19 (OR 19.276, 95 % CI [7,792–47.687], p < 0.001), 4 (OR 4.158, 95 % CI [2.177–7.939], p < 0.001), and 30 (OR 30,000, 95 % CI [9.93–90,610], p < 0.001) times, respectively. The statistical analysis using the univariate logistic regression model revealed that such diseases as coronary artery disease (OR 8,6, 95 % CI [2,6–28,466], p < 0.001), chronic heart failure (CHF) (OR 13,714, 95 % CI [4,784–39,313], p < 0.001), atrial fibrillation (OR 3,455, 95 % CI [1,830–6,525], p < 0.001), type 2 diabetes (OR 2.5, 95 % CI [1,286–4,858[, p = 0.007), postinfarction cardiosclerosis (OR 3,734, 95 % CI [1,953–7,142], p < 0.001), and previous stroke (OR 3,319, 95 % CI [1,519–6,490], p = 0.002) made an independent contribution to death prediction. During the study, we calculated the patients’ serum albumin-to-creatinine ratio (sACR). ROC analysis revealed a cut-off point for sACR to be 0.33 g/mmol as having the best predictive ability of death (AUC — 0.920, 84.3 % sensitivity, 85.29 % specificity). It was established that sACR less than 0.33 g/mmol increased the probability of death by 26 times (OR 26.3806, 95 % CI [9.4573.57], p < 0.001).   CONCLUSION. Serum albumin-to-creatinine content ratio can be used as a predictor of fatal outcome in comorbid patients with thrombotic complications.

31 July 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VPValery I. Podzolkov
Valery I. Podzolkov
ATAida I. Tarzimanova
Aida I. Tarzimanova
EKEvgeniya V. Kazantseva
Evgeniya V. Kazantseva
Aim. To evaluate the prognostic value of pulmonary ventilation disorders in the development of arrhythmia recurrence in patients with chronic obstructive pulmonary disease (COPD) and paroxysmal atrial fibrillation (AF). Materials and methods. The study included 387 patients with COPD, who were divided into two groups: group 1 consisted of 54 (13.9%) patients with COPD and paroxysmal AF, who had AF paroxysm during hospitalization; group 2 (comparison group) – 333 (86.1%) patients with COPD without arrhythmia. Results. Significantly more severe bronchial obstruction was found in group 1 patients than in group 2 patients. A one-factor regression analysis revealed that a decrease in forced exhalation volume in 1st second of less than 35% increased the risk of AF recurrence in patients with COPD by 2.49 times (odds ratio 0.401, 95% confidence interval 0.218–0.856; p=0.012). According to the results of bodyplethysmography, patients in group 1 showed a significant decrease in the diffusion capacity of the lungs for carbon monoxide, an increase in aerodynamic and specific bronchial resistance compared with group 2, a decrease in the diffusion capacity of the lungs of less than 8 ml/min/mm. Mercury increased the risk of AF paroxysm in COPD patients by 1.297 times (odds ratio 0.771, 95% confidence interval 0.53–0.92; p=0.013). To assess the risk of arrhythmia recurrence in patients with COPD and paroxysmal AF, we developed a mathematical model (sensitivity – 73.8%, specificity – 70.3%). Conclusion. Decreased ventilation capacity of the lungs increases the risk of arrhythmia recurrence in patients with COPD and paroxysmal AF.

22 March 2026 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Alexey TarasovAlexey Tarasov
Alexey Tarasov
EKE. V. Kazantseva
E. V. Kazantseva
Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia and is associated with increased cardiovascular complications and mortality. The current patient management paradigm is shifting from a rate control strategy to early and proactive rhythm control, as supported by large randomized trials and current European and Russian guidelines. This review examines the pathophysiological basis of arrhythmogenesis in AF, including the levels of electrical, mechanical, structural, and autonomic atrial remodeling, as well as the key mechanisms of arrhythmia initiation and maintenance (ectopic activity, reentry, trigger activity/delayed afterdepolarizations). Particular attention is paid to the pharmacological strategy of rhythm control using following Vaughan-Williams class I and III antiarrhythmic agents: the molecular targets, pharmacokinetics, clinical efficacy, and safety profile of propafenone, flecainide, lappaconitine hydrobromide (allapinin), ethacizine, amiodarone, sotalol, and others are analyzed, including drugs primarily available in Russia. Based on current data and guidelines, an algorithmic approach to the selection of anti-relapse therapy is proposed, taking into account the patient’s phenotype (paroxysmal or persistent AF, structural myocardial pathology, heart failure coronary artery disease, left ventricular hypertrophy), the level of atrial remodeling, conduction system characteristics, comorbidities, and drug interactions. The characteristics of antiarrhythmic therapy in the early period after cardioversion and after pulmonary vein catheter isolation as part of a hybrid strategy (invasive+drug therapy) are separately discussed. This review is intended for practicing cardiologists and arrhythmologists and aims to facilitate the individualization of antiarrhythmic drug selection within the safe and effective rhythm control strategy for AF.